Abstract: A method/system for sequestering carbon dioxide from cement and lime production facilities wherein carbon dioxide from flue gases originating from cement or lime production facilities is recovered and transported to a building materials production facility where it is sequestered.

Abstract: A method is provided to fabricate a green desiccant wheel. A green recycled adsorbent material of aluminum hydroxide and alumina is extracted and used as a base material to be added to a 3-dimensional (3D) network skeleton of a foam support. Through sintering, surface is hardened with the material adsorbed to megapores uniformly distributed. Thus, an adsorbent material of porous ceramic having pores on surface is made. The area contacting with moist air is increased. The moisture-adsorbing capacity is improved. At last, the whole procedure is integrated to develop a high-efficiency green desiccant wheel. Thus, the reusable materials are kept at innate grade or upgraded for recycling and regenerating. New materials and products can be further fabricated. The present invention helps solving environmental problem of wastes. Life cycle of resource is lengthened. A sample of recycling economy is innovated. Industrial efficiency is effectively enhanced.

Abstract: Embodiments provide inorganic mineral chelated compositions, inorganic and organic salts of minerals, cobalt compounds and compositions, and treatment compositions, and methods of making and using the same. Mineral chelated compositions in combination with mineral salts have been shown to improve plant health, plant emergence, crop yield, plant health consistency, consistent or time-released bio-availability of nutrients in and around a plant, seed, or soil, plant resistance to disease and drought, and microbial catalysis. The compositions described herein can be applied directly to seeds, soil, or plants, or they can be incorporated with existing agricultural treatments and processes, reducing cost and time for farmers to implement the methods described herein. Compositions described herein may also be combined with other commercial products to enhance the efficacy thereof.

Abstract: Aspects of the invention include compositions for enhancing pollination. Dry compositions according to certain embodiments include a carbon skeleton energy compound, macronutrients, a vitamin cofactor composition, micronutrients, an ionophore, and a source of extracted humate. Methods for using the dry compositions of the invention to enhance pollination are also described.

Abstract: An inhibitor composition contains alkyl thiophosphoric triamide (or a mixture of alkyl thiophosphoric triamide and dicyandiamide),dissolved in a liquid medium comprising at least one organic solvent, at least one amine stabilizer and, optionally, at least one dye and/or at least one odor masking agent, is useful in making fertilizer compositions and in a method of fertilizing target plants.

Abstract: An end-burning grain of a solid rocket motor or other gas-generating device is supplemented with one or more sticks of high-burn-rate propellant embedded in a matrix of a relatively low-burn-rate propellant. The sticks increase the burning surface area as the grain burns by forming conical indentations in the surface.

Abstract: Fuel cell arrangement having an improved efficiency. The arrangement comprises one or more fuel cell units 110 and a methanation unit 200 and a control unit 300. The fuel cell unit comprises a water inlet 111, a hydrogen outlet 112 and an oxygen outlet 113. The methanation unit comprises a catalyst 222, a hydrogen inlet 213, a carbon oxide inlet 214 having a first controllable valve 215 and a methane outlet 216, wherein the hydrogen outlet of the first fuel cell unit is coupled to the hydrogen inlet of the methanation unit, and the methanation unit is adapted to convert hydrogen and carbon oxide into methane, wherein the control unit is adapted to control the first controllable valve so as to obtain an optimum converting process to convert hydrogen and carbon oxide into methane.

Abstract: A method of separately producing tert-butanol and sec-butanol, comprising the steps of introducing a mixed butenes stream to a tube side of a reaction membrane unit, introducing a TBA reactor water feed to the tube side of the reaction membrane unit, introducing a sweep gas to a shell side of the reaction membrane unit, introducing an SBA reactor water feed to the shell side, allowing the mixed butenes stream to contact the tube side of a such that selective gases in the mixed butenes stream permeate through the membrane to the shell side, allowing the selective gases that permeate through the membrane to react with water to produce sec-butanol, allowing retentate gases that fail to permeate through the membrane to react with water to produce tert-butanol, collecting the tert-butanol in a TBA reactor effluent, and collecting the sec-butanol in a SBA reactor effluent.

Abstract: A chemoselective process for producing alcohols from ?,?-unsaturated aldehydes and ketones is described.

Abstract: The present invention relates to a novel process for the synthesis of 9,9-bis(hydroxymethyl)fluorene. The syntheses from fluorene to 9,9-bis(hydroxy-methyl)fluorene via a hydroxymethylation and further to 9,9-bis(methoxymethyl)-fluorene via a etherification are known. 9,9-bis(methoxymethyl)fluorene is a compound that is used as an electron donor for Ziegler-Natta catalysts. The present invention is related to an improvement in the synthesis of 9,9-bis(hydroxymethyl)fluorene leading to a decrease in the amount of solvent used and an easier work up while achieving high yield and purity.

Abstract: The disclosure relates to the field of specialty chemicals. In particular, the disclosure provides novel 1,3-fatty-diol compounds and derivatives thereof which are useful e.g., in the production of personal care products, surfactants, detergents, polymers, paints, coatings, and as emulsifiers, emollients, and thickeners in cosmetics and foods, as industrial solvents and plasticizers, etc.

Abstract: Novel biaromatic compounds, which are vitamin D analogs, processes for their preparation and cosmetic, dermatological and pharmaceutical preparations containing one or more of these compounds.

Abstract: In an embodiment, a method for the continuous manufacture of bisphenol A comprises reacting phenol and acetone in the presence of an acidic catalyst to form a product mixture comprising bisphenol A and phenol; directing the product mixture to a crystallization unit comprising a crystallization vessel and a heat exchanger for cooling the product mixture; and crystallizing bisphenol A-phenol adduct crystals from said product mixture in said crystallization unit to form a suspension of crystals; wherein a production rate of the bisphenol A through the heat exchanger is less than or equal to 18 kg bisphenol A per m of a heat exchanging surface per hour.

Abstract: Disclosed are substituted (4?-hydroxylphenyl)cycloalkane compounds and there use as selective agonists of the estrogen receptor beta isoform (ER?). The disclosed compounds may be formulated as pharmaceutical compositions and administered to treat diseases associated with ER activity, such as proliferative diseases and disorders and/or psychiatric diseases or disorders.

Abstract: A process for large scale and energy efficient product of oxygenates from sugar is disclosed in which a sugar feedstock is introduced into a thermolytic fragmentation reactor comprising a fluidized stream of heat carrying particles. The heat carrying particles may be separated from the fluidized stream prior to cooling the fragmentation product and may be directed to a reheater to reheat the particles and recirculate the heated particles to the fragmentation reactor.

Abstract: Disclosed are processes for making such cyclohexanone compositions from a mixture comprising phenol, cyclohexanone, and cyclohexylbenzene. Such cyclohexanone compositions comprise at least 99 wt % cyclohexanone, at most 0.15 wt % water, and at most 500 wppm combined of certain cyclohexanone impurities selected from the group consisting of: benzene, cyclohexene, pentanal, cyclopentanol, cyclohexanol, and phenol.

Abstract: A compound of the formula (I) in which, independently, R1 is selected from H and methyl; R2 is selected from H, and methyl; R3 is selected from H, methyl and ethyl; R4 is selected from H, methyl and ethyl; or R3 and R4 together form a ring in which n is 1 or 2. The compounds have the characteristic desirable odour qualities of the Damascone® molecules, but lack their disadvantageous skin sensitization effects.

Abstract: Disclosed is a process for recovering formic acid from a formate ester of a C3 to C4 alcohol. Disclosed is also a process for producing formic acid by carbonylating a C3 to C4 alcohol, hydrolyzing the formate ester of the alcohol, and recovering a formic acid product. The alcohol may be dried and returned to the reactor. The process enables a more energy efficient production of formic acid than the carbonylation of methanol to produce methyl formate.

Abstract: The present invention relates to an acrylic acid production equipment which includes a raw material gasification apparatus for converting liquefied propylene into a propylene gas; an oxidation reaction apparatus for converting the propylene gas into crude acrylic acid; and a purification apparatus for converting the crude acrylic acid into acrylic acid, wherein the raw material gasification apparatus includes a heating apparatus in the inside thereof and also includes a heating apparatus in the periphery including at least a bottom of the raw material gasification apparatus, by which not only energy can be effectively utilized, but also it is possible to achieve a stopping operation efficiently and within a short time.

Abstract: The present disclosure provides 15-oxo-EPA and 15-oxo-DGLA, compositions comprising 15-oxo-EPA and/or 15-oxo-DGLA, and methods of treating and/or preventing fibrosis, skin disorders, inflammation, kidney disease or renal dysfunction in a subject in need thereof by administering 15-oxo-EPA and/or 15-oxo-DGLA.

Abstract: A diester of a fused ring compound of the formula (I): wherein: the fused rings are both aromatic; R1 and R4 to R6 substituents are H or ester moieties having C1 to C20 linear or branched alkyl chains; R2 and R3 are —C(O)OCxHy, wherein x is from 10 to 12 and y is from 21 to 25; two adjacent R1 to R4 substituents are —C(O)OCxHy, wherein x is from 10 to 12 and y is from 21 to 25; and when R3 and R4 are ester moieties, the alkyl chains of R4 are not C5 or C8; and polymer compositions containing the fused ring compound.

Abstract: Set forth is a process for preparing acrylic acid and/or the ester of acrylic acid and lactic acid from a lactic acid oligomer or polymer. As a result of the use of a bromide source and/or a chloride source in combination with a specific acid, a process that can be operated to obtain a high yield, and is relatively easy to perform, is realized.

Abstract: The present invention relates to a novel process for converting the unwanted S enantiomer form to its useful raceme with respect to a 4-aminoindane derivative.

Abstract: The present invention relates to a pseudo-ceramide compound and a preparation method therefor. According to the present invention, the pseudo-ceramide compound has a molecular structure and a function similar to those of a natural ceramide, can be readily synthesized, and has excellent solubility in an organic solvent and excellent stability, and thus the pseudo-ceramide compound can be used as an alternative to a natural ceramide. Therefore, the pseudo-ceramide compound of the present invention can be widely applied to a skin preparation for external use, a cosmetic composition, and the like for reinforcing and maintaining a skin barrier function.

Abstract: The invention describes pharmaceutical agents capable of crossing the blood brain barrier to protect against organophosphate pesticides and nerve agents or other electrophiles by reactivating inhibited cholinesterase (i.e., acetylcholinesterase and butyrylcholinesterase) and other proteins in the peripheral and central nervous system.

Abstract: A process for preparing aminothiol ester compounds and salts thereof. The present invention relates to a process for preparing compounds of formula (I), (I) comprising the following steps: a) reacting a compound of formula (II) with an inorganic acid or an organic acid, (II) b) reacting the compound obtained in step a) with a base; c) reacting the compound obtained in step b) with CO2; d) reacting the compound obtained in step c) with an alkyl chloroformate, a reagent capable of forming, with the compound obtained in step c), an acid halide, or a reagent capable of forming, with the compound obtained in step c), a mixed anhydride; e) reacting the compound obtained in step d) with an SMe anion precursor compound.

Abstract: Compounds of formula (I): wherein R1 and R2 represent hydrogen or deuterium atoms; R3 represents a hydrogen atom or a —COOH, a —OH or a —OPO(OH)2 group; R4 represents a hydrogen atom or a fluorine atom; R5 represents a hydrogen atom or a —OH group; wherein at least one of R3 or R5 is different from a hydrogen atom; when R3 represents a —COOH, —OH or —OPO(OH)2 group, then R5 represents a hydrogen atom; when R5 represents a —OH group, then R3 and R4 represent hydrogen atoms; and R6 is selected from an optionally substituted phenyl, heteroaryl, cycloalkyl and heterocycloalkyl group; and the preparation and the therapeutic uses of the compounds of formula (I) as inhibitors and degraders of estrogen receptors, useful especially in the treatment of cancer.

Abstract: The present invention provides a production method of a 3-cyanopyrrole compound possibly useful as an intermediate for pharmaceutical products. A production method of compound (II) including subjecting compound (I) to a reduction reaction, in which the aforementioned reduction reaction is continuous hydrogenation reaction in a fixed bed reactor filled with a supported metal catalyst. A production method of compound (III) including subjecting compound (I) to a reduction reaction followed by a cyclization reaction, in which the aforementioned reduction reaction is continuous hydrogenation reaction in a fixed bed reactor filled with a supported metal catalyst.

Abstract: This invention provides compounds of formula I: wherein a, b, c, d, m, n, p, s, t, W, Ar1, R1, R2, R3, R4, R6, R7, and R8 are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and methods of using such compounds to treat pulmonary disorders.

Abstract: The present invention relates to a compound represented by the general formula (I) (wherein the definition of each group has the same meaning as described in the specification). The compound is useful as preventive and/or therapeutic agent for KCNQ2-5 channel-related diseases.

Abstract: Described herein are compounds that are LOXL2 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with LOXL2 activity.

Abstract: 2-((3-(4-cyanonaphthalen-1-yl)pyridin-4-yl)thio)-2-methylpropanoic acid is useful in the modulation of blood or serum uric acid levels. In some embodiments, 2-((3-(4-cyanonaphthalen-1-yl)pyridin-4-yl)thio)-2-methylpropanoic acid is used in the treatment or prevention of disorders related to aberrant levels of uric acid. In some embodiments, 2-((3-(4-cyanonaphthalen-1-yl)pyridin-4-yl)thio)-2-methylpropanoic acid is used for reducing serum uric acid levels in a human. Also described herein are compositions comprising 2-((3-(4-cyanonaphthalen-1-yl)pyridin-4-yl)thio)-2-methylpropanoic acid, and their use in the modulation of blood or serum uric acid levels.

Abstract: The present invention describes novel diamino pyridine derivatives exhibiting JAK modulating properties. The present invention also relates to pharmaceutical compositions comprising these novel compounds, methods of using said compounds in the treatment of various diseases and disorders being susceptible to JAK modulation, and processes for preparing the compounds described hereinafter.

Abstract: The present invention relates to antimicrobial imidazolium compounds having the structure of Formula (I) wherein R is an optionally substituted aliphatic group that is linear, cyclic, saturated, unsaturated or any combination thereof; n is an integer of at least 1; and X is an anionic counterion. The present invention also relates to pharmaceutical composition comprising the compound, a gel comprising the compound, uses of the compound as an antibiotic and methods for the preparation of the gels.

Abstract: Provided herein are dUTPase inhibitors, compositions comprising such compounds and methods of using such compounds and compositions.

Abstract: The present invention provides a salt form and compositions thereof, which are useful as an inhibitor of EGFR kinases and which exhibits desirable characteristics for the same.

Abstract: Provided herein are dUTPase inhibitors, compositions comprising such compounds and methods of using such compounds and compositions.

Abstract: The disclosed subject matter provides methods using and kits comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof.

Abstract: The invention relates to processes for the synthesis of benzodiazepine derivatives of Formula I: (I)

Abstract: A method for treating a lysophosphatidic acid-dependent disease or condition in a subject in need thereof is provided. The method includes administering to the subject a therapeutically effective amount of a heterocyclic compound. The heterocyclic compound is a lysophosphatidic acid receptor ligand. Lysophosphatidic acid-dependent diseases and conditions include diseases involving fibrosis, such as fibrosis of the heart, kidney, liver and lung, and scleroderma; inflammatory diseases such as diabetic nephropathy and inflammatory bowel disease; ocular diseases such as diseases involving retinal degeneration; nerve diseases such as pruritus and pain.

Abstract: The present invention provides compounds of Formula (I), which are “metabolically programmed” metal chelators, e.g., lipophilic, absorbable (e.g., orally absorbable), and effective metal chelators that are converted in vivo to their hydrophilic, nontoxic metabolites. The present invention also provides compounds of Formula (II), which are also “metabolically programmed” metal chelators. The invention also provides pharmaceutical compositions, kits, methods, and uses that include a compound described herein. The compounds, pharmaceutical compositions, kits, and methods may be useful in treating or preventing a disease (e.g., metal overload, oxidative stress, diabetes, liver disease, heart disease, cancer, radiation injury, neurological or neurodegenerative disorder, Friedreich's ataxia (FRDA), macular degeneration, closed head injury, irritable bowel disease, reperfusion injury, metal poisoning, or infectious disease).

Abstract: The present invention includes methods/processes and intermediates for preparing compounds having structural Formula (XI): wherein Y is C1-C12 alkylene or C1-C12 alkenylene; and R8 and R12 are independently C1-C12 alkyl.

Abstract: Provided herein are piperazine carbamates and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful as modulators of MAGL. Furthermore, the subject compounds and compositions are useful for the treatment of pain.

Abstract: The present invention provides a process for forming vinyl-containing compounds including the steps of: a) reacting in a nitrogen atmosphere a dicarboxylic acid and/or anhydride and a functional mono or polyfunctional alcohol to provide a hydroxyl-containing polyester; b) reacting the hydroxyl-containing polyester with a vinyl-containing organic acid in the presence of an esterification catalyst, a polymerization inhibitor and an azeotropic agent; and c) reacting the vinyl functional esterified intermediate, residual esterification catalyst and residual vinyl-containing organic acid with an epoxy to provide the vinyl-containing compound.

Abstract: Compounds of Formula I, including their salts, as well as compositions and methods of using the compounds are set forth.

Abstract: An object of the present invention is to provide a compound having an anti-inflammatory activity or a pharmacologically acceptable salt thereof. The solution of the present invention is a compound of general formula (1) or a pharmacologically acceptable salt thereof. wherein the symbols in the formula are defined below: R1: e.g., a C1-C6 alkyl group; R2: a C1-C6 alkyl group; A: e.g., an oxygen atom; and R3: e.g., a C1-C6 alkyl group.

Abstract: Improved processes for the extraction of quassinoids such as quassin and neoquassin from natural substances containing these compounds are described. The process uses compounds that are Generally Recognized As Safe by the U.S. Food and Drug Administration. In a first embodiment, the process includes a sonication method using water and no organic solvent. The process is highly efficient and comprises fewer steps than other processes known in the art. In a second embodiment, a method of extracting quassinoids from natural substance comprising bark of a plant of the plant family Simaroubaceae is also disclosed. In a third embodiment, indirect sonication of quassinoids is described using a mixture of polar and non-polar organic solvents.

Abstract: A method of purifying a cyclic ester, the method including: granulating a crude cyclic ester, an average particle size of resulting granules being 0.05-1.00 mm; adding the granules to 0-4° C. water to yield a mixture, a mass ratio of the water to the granules being (0.5-2):1; stirring the mixture, and performing solid-liquid separation on the mixture; repeating the stirring and solid-liquid separation for 1-4 times, to yield a purified cyclic ester; drying the purified cyclic ester at 0-4° C. and at an absolute pressure of less than or equal to 10 pascal for 4-6 hours, and continually drying the purified cyclic ester at 40-60° C. and at an absolute pressure of less than or equal to 5 pascal for 1-2 hours.

Abstract: A compound represented by a formula [1D] as shown below (wherein R1A, R1B, R2A, R2B, R3A and R3B represent a hydrogen atom, an optionally substituted C1-6 alkyl group, and the like) is useful as an intermediate for producing a thionucleoside, and the production method of the present invention is useful as a method for producing a thionucleoside.

Abstract: Provided is a novel aromatic amine derivative represented by General Formula (G1) below. (In the formula, A represents oxygen or sulfur, and R1 to R7 individually represent any of a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, a substituted or unsubstituted phenyl group, and a substituted or unsubstituted biphenyl group. In addition, ?1 and ?2 individually represent a substituted or unsubstituted phenylene group. Further, Ar1 represents a substituted or unsubstituted condensed aromatic hydrocarbon having 14 to 18 carbon atoms included in a ring. Further, Ar2 represents a substituted or unsubstituted aryl group having 6 to 13 carbon atoms included in a ring. Further, j and n are individually 0 or 1, and p is 1 or 2.).